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Chronic osteomyelitis is notoriously difficult to eradicate, and high 
treatment failure rates have been reported in the literature.[1,2] Although 
no evidence-based treatment guidelines exist for the management of 
chronic osteomyelitis, the ideal treatment strategy can be outlined as 
judicious resection of all necrotic tissue, dead-space management, and 
neovascularisation of the debridement site followed by soft-tissue and 
bony reconstruction as required.[3-7] Antibiotic therapy is empirically 
initiated as an adjunct to surgical management, and then continued as 
prolonged culture-specific (targeted) therapy.[3]
In the absence of non-invasive sampling methods to ascertain 
the microbiological profile of osteomyelitis, the choice of empirical 
antibiotic therapy to initiate is often aimed at the most probable 
infecting organism, in conjunction with current international 
reports.[8] As the organism and antibiotic susceptibility profiles 
conceivably differ between geographical regions, empirical 
antibiotic strategies should ideally be based on local microbiological 
antibiograms. There are limited data available on the local pathogen 
profiles and antibiograms in developing countries, including South 
Africa (SA).[9]
Objectives
To review the antibiogram profiles of bacterial isolates from 
patients with chronic osteomyelitis of the appendicular skeleton 
who underwent surgical treatment at two high-volume dedicated 
musculoskeletal infection units in Western Cape Province, South 
Africa (SA). Secondary objectives were to evaluate potential empirical 
antibiotic regimens according to the cause of the osteomyelitis, i.e. 
fracture-related infection, haematogenous or contiguous spread.
Methods
A retrospective review of clinical records, microbial culture reports 
and antibiotic susceptibility data was performed for all patients of 
any age who underwent treatment for chronic osteomyelitis between 
1 March 2016 and 31 December 2019. Acute infections (septic 
arthritis and early deep surgical infections), spinal infections and 
periprosthetic joint infections were excluded.
At each institution, all patients were operated on by one of two 
musculoskeletal infection specialist surgeons (NF or ML) during 
the study period. Where cultures were taken from multiple surgical 
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Conclusions. This study reports antibiogram profiles in the developing-world setting that could potentially guide empirical antibiotic 
choices in the management of chronic osteomyelitis.
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interventions, only results from the definitive surgical procedure were 
included. Ethical and hospital board approval (ref. no. N18/08/082) were 
obtained prior to data collection. Chronic osteomyelitis was defined as at 
least 6 months of symptoms, as well as one of the following: 
• sinus, abscess or purulence at the time of surgery
• histological features suggestive of chronic osteomyelitis.
Patients were stratified according to the original pathology into fracture-
related infection, contiguous infection and haematogenous infection 
subgroups. Fracture-related infection was defined according to the 
criteria proposed by Metsemakers et al.[10] and consisted of one of the 
following:
• fistula, sinus or wound breakdown (that communicates to the bone 
or implant)
• purulent drainage or the presence of pus during surgery
• presence of micro-organisms in deep-tissue specimens confirmed by 
histopathological examination.
Contiguous osteomyelitis was defined as an osseous infection that resulted 
from extension from an adjacent soft-tissue infection. Haematogenous 
infection was defined as chronic osteomyelitis that resulted from a de novo 
infection without any local predisposing factors such as trauma, surgery or 
neighbouring infection.
In all cases, intraoperatively collected deep samples of infected tissue 
and/or biofilm were submitted for bacterial culture. Samples were 
submitted to the relevant on-site National Health Laboratory Service 
diagnostic microbiology laboratories at Tygerberg Hospital (TBH) and 
Groote Schuur Hospital (GSH). Solid media used consisted of tryptose 
blood, boiled blood and MacConkey agar (for aerobic/CO2-enriched 
conditions) and Brucella and/or tryptose blood agar (for anaerobic 
conditions). Liquid media used consisted of cooked meat medium or 
tryptic soy broth. Tissue samples were crushed, and crushed tissue and 
pus samples were inoculated onto the basic solid media listed prior to 
incubation. Tissue and pus samples were incubated on solid media only 
for at least 48 hours at TBH; a combination of solid media and broth 
was used at GSH, with solid media incubated for at least 48 hours and 
broth incubated for at least 120 hours, with subculture onto solid media 
if turbid. Pus swabs were incubated on solid media in CO2-enriched 
conditions for a minimum of 24 hours, with anaerobic incubation using 
solid media also included at GSH. Current local laboratory processing 
guidelines do not include the use of sonication or vortexing of the sample 
in the absence of submitted prosthetic material.
All pure cultures were identified. Mixed cultures were reviewed 
by a pathologist and followed up as appropriate. Identification and 
suscep tibility testing were performed using the VITEK 2 automated 
system (bioMérieux, France) with supplemental rapid biochemical or 
antigen-based identification, and disc or gradient diffusion antibiotic 
susceptibility testing, as appropriate. Antibiotic susceptibility results were 
interpreted according to annually published Clinical Laboratory and 
Standards Institute guidelines. For the purposes of this article, organisms 
falling into the intermediate category were categorised as resistant, since 
antibiotic activity at the site of infection was likely to be suboptimal.
Statistical analysis was performed using Stata 16.1 (StataCorp, USA) 
and EpiCalc 2000 v1.02 (Brixton Books, UK). Parametric data are 
reported as means and standard deviations (SDs) with 95% confidence 
intervals (CIs) where appropriate. Non-parametric data are described as 
medians, interquartile ranges and ranges. Categorical data are described 
as frequencies and/or counts, with 95% CIs where appropriate.
Results
Between 1 March 2016 and 31 December 2019, 200 patients with 
chronic osteomyelitis of the appendicular skeleton underwent surgical 
treatment. No patients were excluded. The final cohort comprised 
151 males and 49 females, with a mean (SD) age of 36.0 (14.3) years 
(range 10 - 84; 95% CI 34.0 - 38.0) (Table 1). The distribution of 
affected anatomical sites is shown in Fig. 1.
Microbial isolates
Organisms were isolated from 169 patients (85%), while no 
bacteria were isolated in 31 cases (15%). A pure growth of a 
single organism was cultured from 130 patients (65%), while 
polymicrobial infections were found in 39 cases (20%), with two 
Table 1. Characteristics of patients with chronic osteomyelitis 
at two centres in Cape Town, South Africa (N=200)
Variable
Age (years), mean (SD) 36.0 (14.3)
Sex male, % (n) 151 (76)
Original pathology, % (n)
Fracture-related infection 155 (77)
Haematogenous infection 20 (20)
Contiguous infection 5 (3)
Culture results, % (n)
No growth 31 (16)
Pure culture 130 (65)
Polymicrobial (2 organisms) 32 (16)
Polymicrobial (>2 organisms) 7 (4)
Antibiogram available (N=218 organisms), % (n)
Yes 215 (99)
No (not tested) 3 (1)



















Fig. 1. Anatomical distribution of chronic osteomyelitis cases.
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distinct organisms isolated from 32 patients (16%) and three or 
more organisms from 7 (4%), giving a total of 218 isolates for 
analysis. Of these, 123 (56%) were Gram-positive and 95 (44%) 
were Gram-negative. A full breakdown of bacterial isolates is 
presented in Table 2.
The majority of the organisms (n=174/218; 80%) were isolated 
from fracture-related infections. Gram-positives accounted for 
53% (n=92/174) of the organisms from fracture-related infections. 
Members of the Enterobacterales contributed 55 isolates (32%) 
in this context. The few cases of chronic osteomyelitis due to a 
contiguous source were caused by members of the Enterobacterales 
(n=4/5; 80%). For chronic osteomyelitis following haematogenous 
spread, Gram-positives also predominated (n=30/39; 77%).
Antibiograms
Full antibiogram profiles were obtained for 215 bacterial isolates 
(99%) (Tables 3 and 4). In 3 isolates (1%), all of which were 
anaerobes, no antibiotic susceptibility testing was performed; these 
included 1 case of Clostridium tertium and 2 cases of Finegoldia 
magna.










Methicillin susceptible Staphylococcus aureus 37 24 1 62
Methicillin-resistant S. aureus 20 2 - 22
Coagulase-negative staphylococci* 6 - - 6
Streptococci
Group A Streptococcus 5 1 - 6
Group B Streptococcus 3 - - 3
Group C Streptococcus 1 - - 1
Group G Streptococcus 1 - - 1
S. constellatus 1 1 - 2
Enterococci
Enterococcus faecalis 9 - - 9
Enterococcus species 2 - - 2
Aerobic Gram-positive bacilli
Corynebacterium striatum 2 1 - 3
Corynebacterium species† 1 1 - 2
Enterobacterales
Proteus mirabilis 17 3 2 22
P. hauseri 1 1 - 2
P. penneri - 1 - 1
Enterobacter cloacae 16 - - 16
E. cancerogenus 1 - - 1
Klebsiella pneumoniae 5 1 - 6
K. oxytoca - 1 - 1
K. aerogenes - - 1 1
Serratia marcescens 5 - - 5
Providencia stuartii 2 - - 2
Escherichia coli 1 - 1 2
Morganella morganii 3 - - 3
Citrobacter freundii/braakii 2 - - 2
Other‡ 2 - - 2
Non-fermenting Gram-negative bacilli
Pseudomonas aeruginosa 20 - - 20
Acinetobacter baumannii 6 1 - 7
Ralstonia pickettii - 1 - 1
Miscellaneous Gram-negative bacilli
Aeromonas hydrophlia/caviae 1 - - 1
Anaerobes
Clostridium tertium 1 - - 1
Finegoldia magna 2 - - 2
Bifidobacterium species 1 - - 1
Total 174 39 5 218
*Coagulase-negative staphylococci comprised S. xylosus (n=2) and S. capitis/epidermidis/hominis/saprophyticus (n=1 each).
†Other Corynebacterium species comprised C. amycolatum/minutissimum/species (n=1 each).
‡Other members of the Enterobacterales comprised Leliottia amnigenus 2 (n=1) and Salmonella species (non-typhi) (n=1), both fracture related.
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Key antibiotic susceptibility patterns for selected pathogens are 
summarised below. 
• Staphylococcus aureus (n=84). Cloxacillin susceptibility was 
reported in 62 isolates (74%), clindamycin susceptibility in 67 
(80%) and co-trimoxazole susceptibility in 60 (71%). No reduced 
susceptibility to vancomycin was noted.
• Enterobacterales (n=66). Proteus species, specifically P. mirabilis, 
was the most frequently isolated species (n=22; 33%), followed 
by Enterobacter cloacae (n=16; 24%). Thirty isolates in the 
Enterobacterales group were identified as organisms typically 
harbouring chromosomally encoded class C beta-lactamases 
(45%), and 9 were assumed to harbour extended-spectrum 
beta-lactamases according to Vitek 2 expert analysis (14%). 
No Enterobacterale isolates with reduced susceptibility to the 
carbapenems were identified in this cohort.
• Pseudomonas aeruginosa (n=20). The majority of P. aeruginosa 
isolates were susceptible to one or more first-line agents, with 
80% of isolates testing susceptible to ceftazidime and cefepime, 
and 75% susceptible to piperacillin-tazobactam. All isolates were 
susceptible to amikacin, and 95% were susceptible to gentamicin. 
Ciprofloxacin resistance was observed in 6 isolates (30%).
• Enterococci (n=11). Nine species were ampicillin/amoxicillin 
susceptible (82%). All isolates were susceptible to vancomycin.
• Beta-haemolytic streptococci (n=11). These organisms were 
assumed invariably to be susceptible to penicillin and vancomycin, 
or were susceptible when tested. Clindamycin resistance was 
observed in 2 isolates (18%).
• Acinetobacter baumannii (n=7). Six of the 7 isolates (86%) were 
resistant to all the antibiotics tested, except colistin, for which 
susceptibility was based on Vitek 2. Tigecycline was only tested in 2 
of these isolates, of which both were susceptible. One isolate tested 
susceptible to co-trimoxazole, gentamicin and tobramycin only.
The available resistance data were used to predict the potential 
efficacy of different empirical antibiotic monotherapy or combination 
regimens for bacterial isolates classified according to the original 
pathology (Table 5).
As more than one organism was cultured in 39 cases (20%), the 
resistance data were used to predict potential efficacy of the different 
empirical antibiotic regimens on a per-patient basis (Table 6). In 6 
patients (3%), none of the proposed antibiotic combinations would 
be effective. Combinations of meropenem plus vancomycin and 
piperacillin-tazobactam plus amikacin plus vancomycin would both 
effectively treat 78% of patients with chronic osteomyelitis over 
all infective pathologies. Vancomycin and gentamicin provided 
predicted activity in 75% of patients, and a few locally available 
oral antibiotic combinations displayed similar predicted activity 
rates (co-amoxiclav plus ciprofloxacin 61%, co-trimoxazole plus 
ciprofloxacin 61%, ciprofloxacin plus rifampicin 61%, ciprofloxacin 
plus cloxacillin 60% and ciprofloxacin plus clindamycin 60%).
Discussion
The objective of this study was to review the antibiogram profiles 
of bacterial isolates from patients with chronic osteomyelitis of the 









negative isolates, n (%)
Penicillin 109 27 (25) - -
Ampicillin/amoxicillin 104 28 (27) 37 10 (27)
Co-amoxiclav - - 37 32 (86)
Cloxacillin† 114 81 (71) - -
Ciprofloxacin 101 7 (72) 95 72 (76)
Co-trimoxazole 91 66 (73) 75 43 (57)
Cefuroxime‡ 103 81 (79) 67 28 (42)
Cefotaxime plus ceftriaxone‡ - - 67 58 (87)
Ceftazidime‡ - - 95 74 (78)
Cefepime 104 82 (79) 95 75 (79)
Gentamicin 116 82 (71) 95 78 (82)
Amikacin - - 94 83 (88)
Erythromycin 107 77 (72) - -
Clindamycin 110 79 (72) - -
Vancomycin 120 120 (100) - -
Piperacillin-tazobactam - - 95 75 (79)
Ertapenem - - 67 67 (100)
Imipenem - - 77 59 (77)
Meropenem - - 95 84 (88)
Colistin§ - - 23 23 (100)
Tigecycline - - 35 33 (94)
Linezolid 98 98 (100) - -
Rifampicin 89 66 (73) - -
*Data are presented as counts with frequencies indicated in parentheses. Blank cells refer to organisms intrinsically resistant to the antibiotic tested, or antibiotic that would not be appropriate for 
use in this clinical scenario.
†Cloxacillin calculated for staphylococci only.
‡Organisms with chromosomally encoded ampC enzymes considered to be non-susceptible to second- and third-generation cephalosporins (cefuroxime, ceftriaxone, ceftazidime).
§Colistin/polymyxin E susceptibility testing methodology was revised in 2016 as methods in use were found to be unreliable. All colistin-resistant isolates in this study were intrinsically mediated 
(Proteus, Providencia and Morganella spp.)
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appendicular skeleton who underwent surgical treatment in two 
musculoskeletal infection units in the Western Cape, SA.
The main finding was that our results generally mirrored those of 
Sheehy et al.,[8] published in 2010, which presented the bacteriological 
findings in 166 patients who underwent treatment at the Bone 
Infection Unit at the Nuffield Orthopaedic Centre in Oxford, UK, and 
which similarly described a wide range of bacterial isolates. In both 
studies, S. aureus was the most common bacterium isolated (32% v. 
39% in the present study), with similar proportions of methicillin-
resistant organisms identified (31% v. 26% in the present study).[8] 
These results differ from a 2016 publication by Mthethwa and Marais[9] 
reviewing the bacteriology of chronic osteomyelitis in KwaZulu-Natal 
Province, SA, which instead found the Enterobacterales to be the 
most common causative organisms (34%).
Despite the lack of sonication processing strategies, which 
reportedly increase the bacteriological yield of intraoperative 
specimens, the current series (85%) as well as the one by Mthethwa 
and Marais[9] (93%) showed higher organism culture yields than 
reported by Sheehy et al.[8] (66%). Possible explanations include 
diagnostic criteria employed by the different centres, where Sheehy 
et al.[8] only considered microbial isolates significant if they were 
returned from at least two separate samples. This strategy would 
exclude causative organisms where only one sample is sent, or 
could exclude obligate pathogens if only isolated from one sample. 
Conversely, this strategy prevents causation being ascribed to a 
potential contaminant/colonising organism isolated from a single 
sample. Some pathogens, such as S. aureus and S. pyogenes, are 
usually considered to be significant irrespective of the number of 
samples on which these isolates are identified. Another potential 
explanation for the increased yield of positive cultures is that, in 
our experience, patients with osteomyelitis in the developing-world 
setting are frequently directly referred to tertiary centres without 
initial treatment, which results in an antibiotic-free period at the time 
of presentation.
It is important to note that no antibiotic or antibiotic combination 
was consistently tested across all bacterial isolates, as susceptibility 
was inferred for some regimens (e.g. methicillin-sensitive S. aureus 
was assumed to be susceptible to co-amoxiclav and cephalosporins). 
No proposed empirical antibiotic regimen would effectively treat 
all patients in this series. In terms of parenteral regimens, the 
combinations of meropenem plus vancomycin and piperacillin-
tazobactam plus amikacin plus vancomycin (as a carbapenem-
sparing strategy) would both effectively treat 78% of cases in 
this cohort (mostly fracture-related chronic osteomyelitis). These 
combinations represent our current local protocol and are the two 
most effective parenteral empirical antibiotic regimens across all 
chronic osteomyelitis cases. The combination of meropenem plus 
vancomycin is the empirical antibiotic choice in the Oxford Bone 
Infection Unit.[8] Predicted antibiotic activity was consistently higher 
for haematogenous chronic osteomyelitis cases than for fracture-
related infection.
The frequently used oral empirical antibiotic combination of 
co-trimoxazole plus rifampicin would only have been effective in 49% 
of cases, the empirical oral regimens of clindamycin plus ciprofloxacin 
in 60%, co-trimoxazole plus ciprofloxacin in 61% and ciprofloxacin 
plus rifampicin in 61%. Given the suboptimal predicted activity 
rates of these oral combinations, no empirical oral combination 
can be recommended for patients with chronic osteomyelitis at this 
time. Oral agents can and should still be used in accordance with 
antimicrobial stewardship guidelines and to facilitate outpatient 
management, but this should be targeted to individual patient 
culture. Parenteral regimens should be commenced and continued in 
the postoperative period until individual patient-level susceptibility 
testing data are available. Uncertainty remains in cases where well-
collected samples yield no significant growth, and these patients 
present considerable challenges to clinical teams. In these patients, 
the benefits and risks of broad-spectrum therapy must be weighed 
up against a watch-and-wait strategy, with repeated sampling as 
indicated.
Three anaerobic organisms were identified to species level. C. 
tertium is an anaerobic Gram-positive bacillus and is generally 
considered an uncommon pathogen in humans, although it has 
been isolated from post-traumatic musculoskeletal infections.[11,12] 
F. magna is an anaerobic Gram-positive coccus that forms part of 
the normal flora of the skin and oral cavity.[13] These organisms are 
mostly regarded as contaminants when isolated on culture, although 
Table 6. Proportion of patients who would be covered by various antibiotic regimens based on antibiotic susceptibility testing data, 













Co-amoxiclav 55 (35) 27 (68) 2 (40) 84 (42)
Co-amoxiclav plus ciprofloxacin 89 (57) 30 (75) 3 (60) 122 (61)
Co-trimoxazole plus rifampicin 68 (44) 28 (70) 2 (40) 98 (49)
Co-trimoxazole plus clindamycin 72 (46) 29 (73) 2 (40) 103 (52)
Co-trimoxazole plus ciprofloxacin 89 (57) 29 (73) 3 (60) 121 (61)
Ciprofloxacin plus cloxacillin 86 (55) 30 (75) 3 (60) 119 (60)
Ciprofloxacin plus clindamycin 87 (56) 29 (73) 3 (60) 119 (60)
Ciprofloxacin plus rifampicin 91 (59) 28 (70) 3 (60) 122 (61)
Cefazolin plus ciprofloxacin 85 (55) 30 (75) 3 (60) 118 (59)
Cefazolin plus gentamicin 99 (64) 29 (73) 4 (80) 132 (66)
Cloxacillin plus gentamicin 101 (65) 29 (73) 4 (80) 134 (67)
Vancomycin plus gentamicin 114 (74) 32 (80) 4 (80) 150 (75)
Meropenem plus vancomycin 118 (76) 33 (83) 4 (80) 155 (78)
Piperacillin-tazobactam plus amikacin plus vancomycin 119 (77) 33 (83) 4 (80) 156 (78)
*Data are presented as counts with frequencies indicated in parentheses. Percentages calculated as a proportion of entire subgroup or entire cohort.
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they have been linked to a pathogenic role in prosthetic joint 
infection.[14,15] Many laboratories do not perform susceptibility testing 
for anaerobic organisms, as the recommended methodology is highly 
specialised and/or not cost-effective. There is a concerning trend of 
increasing antibiotic resistance among anaerobic organisms globally, 
highlighting the need to validate simpler and less expensive methods 
for susceptibility testing and to conduct regular resistance surveys.[16]
Local antibiograms can also assist in developing empirical 
antibiotic regimens that can be continued in culture-negative chronic 
osteomyelitis. Failure to culture an organism could be explained by 
the presence of fastidious pathogens that have lost viability prior 
to culture, or by exposure to antibiotics, including those given 
preoperatively as surgical prophylaxis. In this series we failed to 
identify a pathogen in 31 cases (16%) where chronic osteomyelitis 
was diagnosed through local signs (fistula or sinus, the presence 
of pus during surgery, and suggestive histological findings). These 
cases require an antibiotic regimen based on the most likely causative 
organisms. From this series it appears that oral combinations of 
ciprofloxacin plus cloxacillin (60%), ciprofloxacin plus clindamycin 
(60%), ciprofloxacin plus rifampicin (61%) or ciprofloxacin plus 
co-trimoxazole (61%) could be considered in culture-negative cases.
Study limitations
Several limitations limit the generalisability of this study, even 
within SA. These include the retrospective nature of the study 
design and the fact that the bacterial isolates originated from two 
institutions in the same city, which may not be representative 
of other geographical regions. Variability in specimen collection 
and laboratory processing techniques could have affected these 
findings, although these practices were fairly similar between the two 
institutions. Antibiotic susceptibility testing was not uniform between 
institutions, and inferences were made according to guidelines (e.g. 
beta-haemolytic streptococci at GSH were assumed to be susceptible 
to penicillin), hampering conclusive recommendations regarding 
optimal regimens across institutions. As only a single intraoperative 
sample was submitted in the majority of cases, organisms cultured 
were regarded as pathogens in all cases. Most patients in this 
cohort had fracture-related chronic osteomyelitis, limiting robust 
conclusions for the other two subgroups. Despite these limitations, 
this research represents the largest series of antibiograms of bacterial 
isolates from patients with chronic osteomyelitis in SA and can serve 
as a general guideline until similar findings from different regions 
are available. Further studies should investigate haematogenous and 
contiguous chronic osteomyelitis more thoroughly, should emphasise 
susceptibility testing for all oral agents available in our setting to 
draw appropriate conclusions, and should evaluate the impact of the 
empirical antibiotic choices on clinically relevant outcomes.
Conclusions
This study reports information regarding antibiogram profiles of 
chronic osteomyelitis bacterial isolates in the developing-world setting. 
This information may assist decision-making regarding empirical 
antibiotic choices following definitive surgical management, and 
the combinations of meropenem plus vancomycin or piperacillin-
tazobactam plus amikacin plus vancomycin (as a carbapenem-sparing 
strategy) are recommended. It is essential to repeat similar studies 
across settings to inform the development of national guidelines, and 
to repeat these studies periodically and revise guidelines accordingly.
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